PeptiMatrix, an innovative biotechnology company pioneering solutions in animal-free 3D cell culture, has announced the successful closure of its latest funding round. Based at the Biodiscovery Institute in Nottingham, UK, PeptiMatrix is now poised to accelerate its transformative work thanks to this new wave of investment.
A New Chapter for PeptiMatrix
This significant investment marks a turning point in PeptiMatrix's mission to reshape the future of in vitro modelling. Leveraging cutting-edge peptide hydrogel technology, the company is at the forefront of developing next-generation scaffolds for drug development and investigative research. This funding will enable the expansion of research capabilities, enhance product development, and bring life-changing therapies closer to patients worldwide.
"This investment is not just a financial milestone but a strong vote of confidence in our vision," said Dr John Curd, CEO of PeptiMatrix. "With this support, we are one step closer to unlocking the full potential of our technology and transforming the way researchers approach their work."
Meet the Investor
With 33 years of experience as the founder and former CEO of Chevin Fleet Solutions, Ashley Sowerby built a globally recognized leader in fleet management software. Since establishing the company in 1990, he led its growth from a startup to an international provider of innovative solutions that optimize fleet operations for businesses worldwide. Ashley brings his expertise in growing innovative businesses from startup to global provider and will be an invaluable addition to PeptiMatrix’s team as our latest investor and Board observer.
Why This Matters
PeptiMatrix’s innovative technology has the potential to revolutionize how we approach in vitro modelling of development and disease, offering more reliable, reproducible, and ethical solutions. The company’s dedication to scientific excellence and its collaborative ethos have already garnered significant attention within the scientific community.
The Biodiscovery Institute at the University of Nottingham provides an ideal environment for this groundbreaking work, fostering innovation through interdisciplinary collaboration. This latest funding will bolster PeptiMatrix’s ability to translate laboratory breakthroughs into real-world solutions.
Looking Ahead
The future is bright for PeptiMatrix as it gears up to expand its team, deepen its research efforts, and forge new partnerships. With this infusion of support, the company is well-positioned to make waves not only in Nottingham but across the global biotech landscape.
Stay tuned for more updates on PeptiMatrix’s journey as they continue to innovate and inspire in the field of animal-free 3D cell culture.
Get in touch!
If you work in the field of 3D cell culture, and want to find out more about how our innovative, animal-free scaffolds can help accelerate your research, don’t hesitate to get in touch:
Comments